<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[advisory committee and company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/advisory+committee+and+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to advisory committee and company]]></description>
	<s:counts start="0" returned="4" found="4" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Sept_11/ai_n27369312]]></link>
		<description><![CDATA[Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 11 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/amgen+inc..html"><![CDATA[Amgen Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/benefit.html"><![CDATA[benefit]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMGN</category>
		<category domain="tickers">AMGN</category>
	</item>
	<item>
		<title><![CDATA[Riverstone Forms Advisory Committee.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200706/ai_n22559334]]></link>
		<description><![CDATA[VANCOUVER, BRITISH COLUMBIA, Jun 19, 2007 CCNMatthews via COMTEX  -- Riverstone Resources Inc. (the "Company") (TSX VENTURE:RVS)  is pleased to report that an Advisory Committee is being formed to  provide strategic direction to the manageme  VANCOUVER, BRITISH COLUMBIA, Jun 19, 2007 CCNMatthews via COMTEX  --...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 19 Jun 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/riverstone.html"><![CDATA[Riverstone]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Reviews Data on IDM Pharma's Junovan&#153;  for Treatment of Osteosarcoma]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_May_9/ai_n27232653]]></link>
		<description><![CDATA[IRVINE, Calif. -- IDM Pharma, Inc. (NASDAQ: IDMI) today announced that the U.S. Food and Drug Administration's FDA Oncologic Drugs Advisory Committee ODAC voted 12 to 2 that the results of INT 0133, the Phase 3 trial, do not provide substantial evidence of effectiveness of Junovan mifamurtide in the treatment...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 09 May 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Pall Prion Removal Technology Presented to FDA Blood Products Advisory Committee]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_March_17/ai_n13254268]]></link>
		<description><![CDATA[EAST HILLS, N.Y. -- An update on Transmissible Spongiform Encephalopathies TSEs, including variant Creutzfeldt-Jakob Disease vCJD, the human form of "mad cow" disease, was a key topic at the Food & Drug Administration's Blood Products Advisory Committee meeting in Gaithersburg, Maryland today. Issues such as the number of people that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 17 Mar 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pall+corp..html"><![CDATA[Pall Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLL</category>
		<category domain="tickers">PLL</category>
	</item>
</channel>
</rss>
